This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate
by Zacks Equity Research
Lilly (LLY) offers to buy Dermira for $1.1 billion to add the latter's late-stage candidate for atopic dermatitis/eczema, lebrikizumab.
Regeneron's Phase II Candidate Promising in Primary Analysis
by Zacks Equity Research
Regeneron (REGN) announces encouraging results from the phase II study on rare bone disease candidate.
The Zacks Analyst Blog Highlights: JPMorgan, Sanofi, General Electric, American Electric Power and Shopify
by Zacks Equity Research
The Zacks Analyst Blog Highlights: JPMorgan, Sanofi, General Electric, American Electric Power and Shopify
3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2020
by Kinjel Shah
Here we present three non-cancer therapeutic areas wherein pipeline developments are expected to garner a lot of interest in 2020.
Top Stock Reports for JPMorgan, Sanofi & General Electric
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Sanofi (SNY) and General Electric (GE).
Amicus Progresses on Pipeline Development Amid Competition
by Zacks Equity Research
Amicus (FOLD) progresses with the development of its pipeline. However, the company faces substantial competition.
Biotech Leading in Q4: Best ETFs & Stocks
by Sweta Killa
We highlight five biotech ETFs and stocks that are leading the market in Q4.
Amarin Gains on FDA Approval of Vascepa Label Expansion
by Zacks Equity Research
Amarin (AMRN) gains as FDA approves a label expansion of Vascepa to reduce cardiovascular risk.
Pharma Stock Roundup: MRK, SNY to Buy Cancer Firms, LLY Starts New Lung Cancer Study
by Kinjel Shah
This week two deals grab headlines in the pharma space. Merck (MRK) offers to buy ArQule for $2.7 billion while Sanofi (SNY) signs a definitive deal to purchase Synthorx for $2.5 billion
The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, AbbVie, Sanofi, Pioneer Natural Resources and Aqua America
Sanofi, Regeneron to Amend Agreement for Kevzara & Praulent
by Zacks Equity Research
Sanofi (SNY) intends to amend its antibody collaboration with Regeneron related to Kevzara and Praulent into a royalty-based agreement. Agreement terms for Dupixent to remain intact.
Sanofi (SNY) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
Sanofi (SNY) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Top Research Reports for Novartis, AbbVie & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Novartis (NVS), AbbVie (ABBV) and Sanofi (SNY).
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Biotech ETFs Hit New Highs on Deal Activities
by Sweta Killa
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research
by Zacks Equity Research
Sanofi (SNY) to prioritize key growth drivers, improve operating efficiencies and generate cost savings. The company discontinues R&D activities in diabetes and cardiovascular segments.
Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms
by Kinjel Shah
Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.
Week Begins with Biotech Mergers
by Zacks Equity Research
Week Begins with Biotech Mergers
Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More
by Mark Vickery
Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).
Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio
by Zacks Equity Research
Sanofi (SNY) offers to buy Synthorx (THOR) for $2.5 billion. The deal will add Synthorx's lead pipeline asset, THOR-707 to Sanofi's oncology portfolio.
Regeneron Reports Positive Data on Rare Blood Disorder Drug
by Zacks Equity Research
Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.
Alnylam Gets Second Product Approval Amid Stiff Competition
by Zacks Equity Research
Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
Esperion's Promising Drugs Under Review, Funds a Concern
by Zacks Equity Research
Esperion's (ESPR) regulatory applications for bempedoic acid monotherapy and combo seeking approval for lowering LDL-C are under review. However, absence of adequate funds may jeopardize the launch.
Novartis (NVS) to Acquire The Medicines Company for $9.7B
by Zacks Equity Research
Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.
Amarin's Shares Down on Underperform Rating by Oppenheimer
by Zacks Equity Research
Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.